Eevia Health Plc’s (“Eevia”) shares will be listed on Spotlight Stock Market today, June 29, 2021

Eevia Health Plc recently succeeded with an IPO equity round, issuing new 3 451 000 shares with gross proceeds of approx. SEK 26,2 million, leading to a total of 13 951 500 shares in the company as per today's date. Trading in shares will take place from today, June 29, 2021 at Spotlight Stock Market. The short name for the share is EEVIA.

Stein Ulve, CEO: “It is exciting to see Eevia Health listed at Spotlight Stock Market. It is a significant milestone for our Company. Now we may continue focusing on creating growth and value for all constituents of our venture."

See also: Start | Spotlight (spotlightstockmarket.com)


Information about the Eevia Health shares:

Short name:                                 EEVIA 

Share name:                                Eevia Health

ISIN-code:                                    FI4000496658

Orderbook-ID:                              85FD

CFI:                                              ESVUFR

FISN:                                           EEVIA HEALTH/SH

Organization number:                  2825194-4

LEI:                                              743700NO7D0UA8J1MQ31  

Market Segment:                         SPSE

MIC code:                                    XSAT

Tick table/liquidity band #:          1 (Shares and depositary receipts)


Seinäjoki, Finland June 29, 2021

 

For more information, please contact: 

Stein Ulve, CEO                                                     Kim Nurmi-Aro, CFO

stein.ulve@eeviahealth.com                                 kim@eeviahealth.com

Tel.: +358 400 22 5967                                        +358 504 44 0717

 

About Eevia

Eevia was founded in 2017 with the mission to address global health problems through the sustainable production and distribution of bioactive plant extracts, which have scientifically documented health benefits. Through utilization of raw material sources, often under-utilized raw materials abundantly available in the Nordic forests, and sometimes inexpensive by‐products from food and wood‐industries, Eevia manufactures and markets organically certified nutraceutical ingredients. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute strong and significant macro-trends. Eevia stands well equipped to capitalize from these trends, resulting in an accelerating growth trajectory.

Eevia is headquartered in Seinäjoki, Finland. As of the end of 2020, the Company had 28 full-time employees and its total revenue for the full year ended December 31st, 2020 was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January – 31st March, corresponding to 560 percent sales growth compared to the same period prior year.